• CPC Scientific’s Tirzepatide API Successfully Secures US FDA DMF Filing

    CPC Scientific, a premier peptide and oligonucleotide-focused CRDMO and a wholly owned subsidiary of Medtide Inc. (HKEX: 3880.HK), today announced that its Hangzhou-based CGMP manufacturing facility, Chinese Peptide Company, has successfully completed the Drug Master File (DMF) filing for its self-developed Tirzepatide active pharmaceutical ingredient (API) with the U.S. Food and Drug Administration (FDA) under DMF number 043979.

    Published On: May 29th, 2026Categories: Press Releases
  • What is a CDMO, and How Does Partnering With One Accelerate Your Programs?

    Selecting the right partner can directly impact both speed-to-market and long-term commercial success, particularly for peptide and oligo programs. A CDMO addresses this by providing support across the drug development lifecycle.

    Published On: October 7th, 2025Categories: Articles
  • CPC Scientific to Showcase Peptide and Oligonucleotide CDMO Leadership at CPHI Frankfurt 2025

    At CPHI Frankfurt 2025, CPC Scientific will spotlight its position as a global leader in peptide and oligonucleotide CRDMO solutions. As the company’s largest event of the year, the showcase will emphasize innovation, regulatory excellence, and a proven track record of supporting partners worldwide. Visitors can connect with CPC Scientific’s leadership and scientific team at Booth 12.0F29 to explore new opportunities and collaborations.

    Published On: October 1st, 2025Categories: Press Releases